Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sulbactam-Durlobactam in Pediatric Patients with Acinetobacter Baumannii-calcoaceticus Complex Infection
NCT06801223Phase 1Recruiting
- Sponsor
- Innoviva Specialty Therapeutics
- Start
- Dec 2026
- Primary completion
- May 2028
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label trial of sulbactam and durlobactam in Acinetobacter baumannii-calcoaceticus complex infection (6 cohorts), sponsored by Innoviva Specialty Therapeutics. Primary endpoints: Maximum Concentration at Day 3 and Area Under the Plasma Concentration-Time Curve from 0 to 24 hours. Planned start Dec 2026; status: recruiting.
02
Drugs
sulbactamdurlobactam
03
Conditions
Acinetobacter baumannii-calcoaceticus complex infection
Beyond the preview
Go deeper on NCT06801223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06801223.